Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status Prescription
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 0069-8141; 53869-2231; 68724-1020; 0069-8140; 72969-115; 53869-2230
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eyelid ptosis06.05.01.002; 17.17.02.0040.000533%Not Available
Face oedema08.01.07.003; 23.04.01.004; 10.01.05.0020.001332%
Facial paralysis17.04.03.008--Not Available
Faeces discoloured07.01.03.002--Not Available
Fatigue08.01.01.0020.042626%
Febrile neutropenia08.05.02.004; 01.02.03.002--
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.0090.001865%Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Fibrosis08.03.01.0010.000139%Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.0070.000799%
Flatulence07.01.04.0020.004263%
Fluid retention20.01.02.003; 14.05.06.0020.006394%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Foot fracture15.08.03.012; 12.04.01.012--Not Available
Fracture15.08.02.001; 12.04.02.001--
Fungal infection11.03.05.001--Not Available
Gait disturbance08.01.02.002; 17.02.05.016--
Gamma-glutamyltransferase increased13.03.01.0110.002664%
Gastric cancer16.13.03.001; 07.21.02.0010.000278%Not Available
Gastric perforation12.02.03.007; 07.04.03.0010.000799%
Gastric ulcer07.04.03.002--
Gastritis07.08.02.0010.001332%
Gastrooesophageal reflux disease07.02.02.0030.006660%
Gastroenteritis11.01.07.004; 07.19.03.0010.001066%Not Available
Gastroenteritis viral07.19.03.005; 11.05.04.005--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal perforation07.04.04.001--Not Available
Generalised oedema14.05.06.007; 08.01.07.0040.002131%
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 20 Pages